Close

Jubilant HollisterStier Signs Manufacturing Agreement with Eli Lilly for COVID-19 Therapeutic Bamlanivimab

Related stories

Pharmacy’s Impact on Reducing Medication Errors in Hospital Settings

Medication errors are a big problem in healthcare because...

How to Dispose of Pharmaceutical Waste

Proper pharmaceutical waste disposal is crucial for protecting our...

Semaglutide 101: What You Need to Know About This Game-Changing Medication

In the realm of modern medicine, breakthroughs are not...

Health Benefits of Pre-work Supplements

Whether you are a workout expert or just starting...

AI-Driven Pharmacovigilance with Real-Time Data Monitoring

Pharmacovigilance is about looking out for bad stuff from...

Jubilant Life Sciences Ltd, an integrated global Pharmaceuticals and Life Sciences Company, recently announced that its wholly-owned subsidiary, Jubilant Pharma Limited, through one of its subsidiaries, Jubilant HollisterStier LLC , has signed new contract with Eli Lilly for contract manufacturing of a treatment for COVID-19. The drug will be manufactured at the Spokane, Washington, USA facility of the Company.

Commenting on the occasion, Mr. Pramod Yadav, CEO, Jubilant Pharma Limited, said: “We are delighted to partner with our customers and contribute towards the fight against COVID-19 pandemic. Our CMO business, an established player in the North American market, has strong capabilities in the manufacturing of sterile injectables (both liquid and lyophilisation) and we are committed to continue exceeding expectations of our customers in this business. One of our subsidiaries, Jubilant HollisterStier LLC, has signed a contract with Eli Lilly and Company (Lilly), for contract manufacturing of Bamlanivimab, a drug that has been granted Emergency Use Authorization by the FDA for emergency use as a treatment of COVID 19. Jubilant HollisterStier is part of Lilly’s network of external manufacturing organizations that is producing the drug. The drug will be manufactured by Jubilant HollisterStier at the company’s Spokane, Washington, USA facility.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories